Skip to main content

Esophageal Cancer Clinical Trials

Review the esophageal cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 129

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Status: Active
Location: 4 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Status: Active
Location: 4 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Status: Active
Location: 4 locations
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Status: Active
Location: 5 locations
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Status: Active
Location: 4 locations
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Status: Active
Location: 4 locations
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Status: Active
Location: 4 locations
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Status: Active
Location: 3 locations
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Status: Active
Location: 3 locations
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Status: Active
Location: 3 locations
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Status: Active
Location: 3 locations
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Status: Active
Location: 3 locations
Oncolytic Adenovirus CAdVEC and HER2 Specific CAR T Cells for the Treatment of Advanced or Refractory HER2 Positive Solid Tumors, VISTA Study
Status: Active
Location: 3 locations
Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer
Status: Active
Location: 3 locations
Study of INCB123667 in Subjects With Advanced Solid Tumors
Status: Active
Location: 3 locations
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: 2 locations
Emavusertib in Combination with Combination Chemotherapy and Immunotherapy with or without Trastuzumab for the Treatment of Advanced Unresectable or Metastatic Gastric or Esophageal Cancer
Status: Active
Location: 2 locations
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Status: Active
Location: 2 locations
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Status: Active
Location: 2 locations
Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Preoperative Hypofractionated Radiotherapy with FOLFOX for the Treatment of Stage I-III Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: 2 locations
Neratinib in Combination with Chemotherapy, Trastuzumab, Pembrolizumab in Patients with Stage HER2 Overexpressing Stage IV Gastroesophageal Cancers
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Propranolol in Combination with Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York